The US Food and Drug Administration (FDA) approved the first sublingual allergen extract for treatment of allergic rhinitis, in this case for symptoms induced by exposure to grass pollen, on April 2 (http://1.usa.gov/1mKpSNe).
A growing body of evidence has suggested that desensitizing patients with allergies by sublingual exposure to tiny amounts of allergen may be effective. The new product, Oralair, consists of freeze-dried extracts of pollen from 5 common grasses (Kentucky bluegrass, orchard, perennial rye, sweet vernal, and Timothy).
Kuehn BM. FDA Approves First Sublingual Therapies for Allergic Rhinitis. JAMA. 2014;311(20):2057. doi:10.1001/jama.2014.5757